We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
26
BlackRock
New York
$55.4M +$112K +820 +0.2%
Voloridge Investment Management
27
Voloridge Investment Management
Florida
$47.2M +$5.27M +38,719 +13%
FAM
28
Fred Alger Management
New York
$41.9M +$16.5M +120,952 +65%
American Century Companies
29
American Century Companies
Missouri
$41.7M -$22.7K -167 -0.1%
RSCM
30
Rock Springs Capital Management
Maryland
$39.6M – – –
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$38.4M -$7.97M -58,581 -17%
SEI Investments
32
SEI Investments
Pennsylvania
$36.1M -$11.1M -81,615 -24%
Two Sigma Investments
33
Two Sigma Investments
New York
$34.8M +$6.12M +44,995 +21%
AIP
34
ARS Investment Partners
New York
$34.5M -$249K -1,828 -0.7%
Bank of America
35
Bank of America
North Carolina
$33.7M -$2.38M -17,484 -7%
SPPAM
36
Summit Partners Public Asset Management
Massachusetts
$31.9M +$1.16M +8,562 +4%
TLP
37
Tri Locum Partners
New York
$31.1M +$15.7M +115,092 +102%
QGA
38
Q Global Advisors
Texas
$29.9M -$8.92M -65,541 -23%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$27.5M +$5.25M +38,600 +24%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$27.2M +$452K +3,322 +2%
WP
41
Woodline Partners
California
$27.1M +$372K +2,736 +1%
CS
42
Candriam SCA
Luxembourg
$26.6M +$13.1M +95,972 +97%
FC
43
Finepoint Capital
Massachusetts
$25.8M +$1.85M +13,600 +8%
FTM
44
First Turn Management
California
$25.4M +$4.76M +34,994 +23%
Deutsche Bank
45
Deutsche Bank
Germany
$24.7M -$10.9M -80,000 -31%
Allspring Global Investments
46
Allspring Global Investments
North Carolina
$24.4M -$1.35M -9,956 -5%
Morgan Stanley
47
Morgan Stanley
New York
$22.8M +$2.03M +14,917 +10%
BNP Paribas Asset Management
48
BNP Paribas Asset Management
France
$22.2M +$10.5M +76,908 +89%
Aberdeen Group
49
Aberdeen Group
United Kingdom
$21.9M +$2.97M +21,811 +16%
RHJA
50
Rice Hall James & Associates
California
$20.7M -$1.46M -10,756 -7%
1
2
3 4 5

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.